<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32790757</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Use of vitamins by participants in amyotrophic lateral sclerosis clinical trials.</ArticleTitle><Pagination><StartPage>e0237175</StartPage><MedlinePgn>e0237175</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0237175</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0237175</ELocationID><Abstract><AbstractText>Patients' vitamin intake is often not documented and is therefore not considered sufficiently in studies of prescribed medication in patients with amyotrophic lateral sclerosis (ALS). We aimed to determine the prevalence of vitamin use by participants in ALS clinical trials. Data about demographics, disease severity (ALS Functional Rating Scale) and concomitant medication were obtained from the Pooled Resource Open-Access ALS Clinical Trials Database, which contains records from more than 6000 ALS patients who participated in 23 phase II/III clinical trials. Information about vitamin intake for all study subjects was coded into major categories. Clinical data of vitamin users and nonusers were compared, and regression analysis was used to explore the associations among clinical parameters, vitamin use and two measures of disease progression. From the 40.996 available medication records from 6274 subjects, 7338 (17.9%) concerned vitamins. One or more vitamins were used by 3331 subjects (53.1%). Most common was vitamin E, vitamin C and multivitamins. Patients who did and did not take vitamins did not differ in terms of disease progression and ALS Functional Rating Scale score. Patients who took vitamins were younger, were more often female, had a shorter time between onset and diagnosis, had shorter disease duration and more frequently had limb-onset types. Disease progression rate and disease aggressiveness were not associated with vitamin use. Despite unclear evidence, the use of vitamins in ALS is common. However, rapid progression was not observed to be associated with vitamin use.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prell</LastName><ForeName>Tino</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6423-3108</Identifier><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Ageing, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosskreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Ageing, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Pooled Resource Open-Access ALS Clinical Trials Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014815">Vitamins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32790757</ArticleId><ArticleId IdType="pmc">PMC7425848</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0237175</ArticleId><ArticleId IdType="pii">PONE-D-20-15953</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3(1). 10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):324&#x2013;31. 10.3109/17482960903009054</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903009054</ArticleId><ArticleId IdType="pubmed">19922119</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, Kettemann D, Maier A, Grehl T, Weyen U, Grosskreutz J, et al. Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. J Neurol Neurosurg Psychiatry. 2020. 10.1136/jnnp-2020-322938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322938</ArticleId><ArticleId IdType="pmc">PMC7361015</ArticleId><ArticleId IdType="pubmed">32317400</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719&#x2013;25. 10.1212/WNL.0000000000000951</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302&#x2013;9. 10.1212/WNL.0000000000004029</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, Stubendorff B, Le TT, Gaur N, Tadi&#x107; V, R&#xf6;diger A, et al. Reaction to endoplasmic reticulum stress via ATF6 in amyotrophic lateral sclerosis deteriorates with aging. Front Aging Neurosci. 2019;11:5 10.3389/fnagi.2019.00005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00005</ArticleId><ArticleId IdType="pmc">PMC6355670</ArticleId><ArticleId IdType="pubmed">30740050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, O&#x2019;Reilly &#xc9;J, Weisskopf MG, Logroscino G, McCullough ML, Schatzkin A, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol. 2011;173(6):595&#x2013;602. 10.1093/aje/kwq416</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq416</ArticleId><ArticleId IdType="pmc">PMC3105261</ArticleId><ArticleId IdType="pubmed">21335424</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39(2):147&#x2013;157. 10.1002/ana.410390203</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390203</ArticleId><ArticleId IdType="pubmed">8967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(1):9&#x2013;18. 10.1080/146608201300079364</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608201300079364</ArticleId><ArticleId IdType="pubmed">11465936</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna). 2005;112(5):649&#x2013;60. 10.1007/s00702-004-0220-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-004-0220-1</ArticleId><ArticleId IdType="pubmed">15517433</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP. Antioxidant therapy in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1;Suppl 4:5&#x2013;12. 10.1080/14660820050515656</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820050515656</ArticleId><ArticleId IdType="pubmed">11466960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;1:CD011776 10.1002/14651858.CD011776.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011776.pub2</ArticleId><ArticleId IdType="pmc">PMC6469543</ArticleId><ArticleId IdType="pubmed">28072907</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald KC, O&#x2019;Reilly &#xc9;J, Fondell E, Falcone GJ, McCullough ML, Park Y, et al. Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: pooled results from 5 cohort studies. Ann Neurol. 2013;73(2):236&#x2013;45. 10.1002/ana.23820</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23820</ArticleId><ArticleId IdType="pmc">PMC3608702</ArticleId><ArticleId IdType="pubmed">23362045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond L, Bowen G, Mertens B, Denson K, Jordan K, Vidakovic B, et al. Associations of patient mood, modulators of quality of life, and pharmaceuticals with amyotrophic lateral sclerosis survival duration. Behav Sci (Basel). 2020;10(1). 10.3390/bs10010033</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bs10010033</ArticleId><ArticleId IdType="pmc">PMC7016647</ArticleId><ArticleId IdType="pubmed">31936812</ArticleId></ArticleIdList></Reference><Reference><Citation>Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2007;1:CD002829 10.1002/14651858.CD002829.pub4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002829.pub4</ArticleId><ArticleId IdType="pubmed">17253482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogovik AL, Vohra S, Goldman RD. Safety considerations and potential interactions of vitamins: should vitamins be considered drugs? Ann Pharmacother. 2010;44(2):311&#x2013;324. 10.1345/aph.1M238</Citation><ArticleIdList><ArticleId IdType="doi">10.1345/aph.1M238</ArticleId><ArticleId IdType="pubmed">20040703</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>